Eurofins has expanded its services with a couple recent acquisitions. First it signed an agreement with Tata Group to acquire Advinus Therapeutics, a preclinical and clinical phase contract research company for safety assessment, DMPK, CMC services, and analytical R&D services. Located in Bangalore, India, the company operates a state-of-the art 20,000 square meter facility on a large campus with space for expansion.

Advinus’ expertise complements Eurofins recent contract research, development and manufacturing capabilities following the acquisitions of Alphora in Canada and Amatsigroup in Europe. The company provides GMP testing and manufacturing capabilities, and is positioned to capitalize on the growing R&D outsourcing market in the Asia-Pacific region.

Eurofins also expanded its offering and footprint in drug discovery services with the acquisition of DiscoverX, which offers drug discovery products and services across all stages of discovery from target identification and lead discovery to preclinical and beyond.

DiscoverX develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other disruptive solutions for the drug discovery, screening, and life science markets. The company has over 15 years’ experience in drug discovery and development leveraging on the Enzyme Fragment Complementation (EFC) technology. With over 900 stable cell lines, 4500 drug discovery assays and kits, and both custom and off-the shelf services, DiscoverX offers a broad drug discovery portfolio. The company operates in four locations in Fremont, San Diego, San Francisco (California) and Birmingham (England).

The combination of Eurofins Pharma Discovery Services and DiscoverX provides the pharmaceutical and biotech industries with a partner for end-to-end drug discovery services, enabling customers to improve research productivity and effectiveness of their screening, lead optimization and structure-activity relationships (SAR) campaigns, thus accelerating the discovery and development of new drugs. In addition, DiscoverX’s KINOMEscan platform and epigenetics services, combined with Eurofins Pharma Discovery’s kinase profiling services would result in the largest available portfolio of kinase products and services in the market.

DiscoverX’s expertise complements Eurofins discovery pharmacology capabilities following the previous acquisitions of Panlabs, Cerep, EMD Millipore Discovery and Development Solutions and Villapharma.